Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOPPatrizia Pregno, Umberto Vitolo, Francesca Giunta et al.|Blood|2012Cited by 238
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experienceChiara Ciochetto, Umberto Vitolo, Barbara Botto et al.|Annals of Hematology|2018Cited by 7
The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.Umberto Vitolo, G Bisi, Annalisa Chiappella et al.|Blood|2010Cited by 4